SAM
LGND icon

Silvercrest Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Silvercrest Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-64,362
Closed -$4.19M – 752
2019
Q4 		$4.19M Sell
64,362
-18,999
-23% -$1.27M 0.03% 387
2019
Q3 		$5.18M Buy
+83,361
New +$5.23M 0.04% 328

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Silvercrest Asset Management's LGND Position: Q1 2020 in Review

Silvercrest Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 64,362 shares — an estimated $4.19M sold.

Silvercrest Asset Management first reported a position in LGND in Q3 2019 and held it in 2 quarters. The position peaked at $5.18M in Q3 2019. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Silvercrest Asset Management reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Silvercrest Asset Management sold 64,362 Ligand Pharmaceuticals shares in Q1 2020, an estimated $4.19M.
  • Silvercrest Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Silvercrest Asset Management's Ligand Pharmaceuticals position peaked at $5.18M in Q3 2019.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Silvercrest Asset Management's 13F filing for Q1 2020, filed 15 May 2020.